ResearchMoz

Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies

GBI Research
Published Date » 2013-12-03
No. Of Pages » N/A
   
 GBI Research has released its pharma research, "Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies", which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications....
Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 5
2.1 Ophthalmology Therapeutics in Major Markets is Expected to Reach $6.1 Billion by 2019, with Growth of 7.6% 5
2.2 Moderate Pipeline with Promising Drugs in Late Stages of Development could Drive Market Expectations 7

3 Ophthalmology Therapeutics in Major Markets – Introduction 9
3.1 Dry Eye Syndrome 9
3.1.1 Classification 9
3.1.2 Symptoms 9
3.1.3 Etiology 9
3.1.4 Pathophysiology 10
3.1.5 Diagnosis 11
3.1.6 Epidemiology 12
3.1.7 Prognosis 13
3.1.8 Treatment Options 13
3.2 Glaucoma 14
3.2.1 Classification 14
3.2.2 Symptoms 15
3.2.3 Etiology 15
3.2.4 Pathophysiology 16
3.2.5 Diagnosis 16
3.2.6 Epidemiology 17
3.2.7 Prognosis 18
3.2.8 Treatment Options 18
3.3 GBI Research Report Guidance 19

4 Ophthalmology Therapeutics in Major Markets – Marketed Products (Global) 19
4.1 Dry Eye Syndrome 19
4.2 Glaucoma 20
4.3 Key Marketed Products 21
4.3.1 Restasis 21
4.3.2 Systane 22
4.3.3 Diquas 23
4.3.4 Mucosta 24
4.3.5 Hyalein 25
4.3.6 Lumigan 26
4.3.7 Alphagan/Alphagan P 27
4.3.8 Simbrinza 28

5 Ophthalmology Therapeutics in Major Markets – Pipeline Analysis 28
5.1 Dry Eye Syndrome Pipeline 28
5.1.1 Overall Pipeline 28
5.1.2 Pipeline Analysis by Molecule Type 31
5.1.3 Pipeline Analysis by Mechanism of Action 33
5.2 Glaucoma Pipeline 35
5.2.1 Overall Pipeline 35
5.2.2 Pipeline Analysis by Molecule Type 37
5.2.3 Pipeline Analysis by Mechanism of Action 39
5.3 Promising Drug Candidates in the Pipeline 41
5.3.1 CF-101 41
5.3.2 MIM-D3 41
5.3.3 SAR-1118 41
5.3.4 DE-111 42

6 Ophthalmology Therapeutics in Major Markets – Market Forecast to 2019 42
6.1 Major Markets 42
6.1.1 Treatment Usage Patterns 42
6.1.2 Annual Cost of Therapy 42
6.1.3 Market Size 42
6.2 The US 44
6.2.1 Treatment Usage Patterns 44
6.2.2 Annual Cost of Therapy 44
6.2.3 Market Size 44
6.3 Top Five European Countries 46
6.3.1 Treatment Usage Patterns 46
6.3.2 Annual Cost of Therapy 46
6.3.3 Market Size 46
6.4 Canada 48
6.4.1 Treatment Usage Patterns 48
6.4.2 Annual Cost of Therapy 48
6.4.3 Market Size 48
6.5 Japan 50
6.5.1 Treatment Usage Patterns 50
6.5.2 Annual Cost of Therapy 50
6.5.3 Market Size 50
6.6 Drivers and Barriers 52
6.6.1 Drivers 52
6.6.2 Barriers 52

7 Ophthalmology Therapeutics in Major Markets – Deals and Strategic Consolidations (Global) 53
7.1 Deals Analysis 53
7.2 Major Co-Development Deals 55
7.2.1 NicOx Signs Research Agreement with Pfizer 56
7.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 56
7.2.3 Akorn Enters into Agreement with Azad Pharma 56
7.3 Major Licensing Deals 57
7.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 58
7.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 58
7.3.3 Asterand Enters into Licensing Agreement with Allergan 58

8 Ophthalmology Therapeutics in Major Markets – Appendix 58
8.1 All Pipeline Drugs by Phase 58
8.1.1 Discovery 58
8.1.2 Preclinical 59
8.1.3 IND/CTA-filed 60
8.1.4 Phase I 60
8.1.5 Phase II 62
8.1.6 Phase III 63
8.1.7 Pre-registration 63
8.1.8 Undisclosed 64
8.2 Market Forecasts to 2019 64
8.2.1 Major Markets 64
8.2.2 The US 65
8.2.3 The UK 65
8.2.4 France 66
8.2.5 Germany 67
8.2.6 Italy 67
8.2.7 Spain 68
8.2.8 Canada 69
8.2.9 Japan 69
8.3 Market Definitions 70
8.4 Abbreviations 70
8.5 Sources 72
8.6 Research Methodology 73
8.6.1 Coverage 74
8.6.2 Secondary Research 74
8.6.3 Primary Research 74
8.6.4 Therapeutic Landscape 75
8.6.5 Geographical Landscape 78
8.6.6 Pipeline Analysis 78
8.7 Expert Panel Validation 78
8.8 Contact Us 78
8.9 Disclaimer 78

List of Tables


Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 13
Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 14
Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 18
Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 58
Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 59
Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 60
Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 60
Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 62
Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 63
Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 63
Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 64
Table 12: Ophthalmology Therapeutics Market, Major Markets,, Dry Eye Syndrome, Market Forecast, 2012–2019 64
Table 13: Ophthalmology Therapeutics Market, Major Markets, Glaucoma, Market Forecast, 2012–2019 64
Table 14: Ophthalmology Therapeutics Market, The US, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 15: Ophthalmology Therapeutics Market, The US, Glaucoma, Market Forecast, 2012–2019 65
Table 16: Ophthalmology Therapeutics Market, The UK, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 17: Ophthalmology Therapeutics Market, The UK, Glaucoma, Market Forecast, 2012–2019 66
Table 18: Ophthalmology Therapeutics Market, France, Dry Eye Syndrome, Market Forecast, 2012–2019 66
Table 19: Ophthalmology Therapeutics Market, France, Glaucoma, Market Forecast, 2012–2019 66
Table 20: Ophthalmology Therapeutics Market, Germany, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 21: Ophthalmology Therapeutics Market, Germany, Glaucoma, Market Forecast, 2012–2019 67
Table 22: Ophthalmology Therapeutics Market, Italy, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 23: Ophthalmology Therapeutics Market, Italy, Glaucoma, Market Forecast, 2012–2019 68
Table 24: Ophthalmology Therapeutics Market, Spain, Dry Eye Syndrome, Market Forecast, 2012–2019 68
Table 25: Ophthalmology Therapeutics Market, Spain, Glaucoma, Market Forecast, 2012–2019 68
Table 26: Ophthalmology Therapeutics Market, Canada, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 27: Ophthalmology Therapeutics Market, Canada, Glaucoma, Market Forecast, 2012–2019 69
Table 28: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 29: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012–2019 70

List of Figures


Figure 1: Ophthalmology Therapeutics Market, Major Markets, Market Size (bn), 2012–2019 6
Figure 2: Ophthalmology Therapeutics Market, Global, Pipeline by Stage (%), 2013 8
Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006–2012 21
Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010–2012 23
Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009–2012 24
Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009–2012 25
Figure 7: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006–2012 26
Figure 8: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006–2012 27
Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 29
Figure 10: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 32
Figure 11: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 34
Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 36
Figure 13: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 38
Figure 14: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 40
Figure 15: Ophthalmology Therapeutics Market, Major Markets, Market Size, 2012–2019 43
Figure 16: Ophthalmology Therapeutics Market, The US, Market Size, 2012–2019 45
Figure 17: Ophthalmology Therapeutics Market, Top Five European Countries, Market Size, 2012–2019 47
Figure 18: Ophthalmology Therapeutics Market, Canada, Market Size ($m), 2012–2019 49
Figure 19: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012–2019 51
Figure 20: Ophthalmology Therapeutics Market, Global, Deals, 2006–2013 54
Figure 21: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006–2013 55
Figure 22: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006–2013 57
Figure 23: GBI Research Market Forecasting Model 77

Upcoming Reports:

Electric Accumulators Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Electric accumulators, commonly known as rechargeable batteries, are extensively used in various industrial sectors. They find applications in fields such as activated carbon, audio-visual equipments, and coating machines among many others. These accumulators include motor vehicle lead-acid, nickel-cadmium (NiCad) and the newly developed nickel-metal hydride (NiMH), and lithium ion polymer (LiPoly or LiPo) type batteries. The market for electric accumulators is concentrated in the European region followed by Asia Pacific. Regions such as North America and the rest of world exhibit an...
Hog Production And Pork Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Pigs are the species of animals that belong to Suidae family, are generally farmed for the production of meat. Pigs are commonly known as hogs in the U.S. The meat produced from hogs is termed as pork. One can farm pigs in open field by allowing it to wander freely, in restricted field by providing proper food or in special houses in modern countries. In recent years, the pig farming industry has been diversifying from the traditional one in order to produce higher yields of pork. To get good quality and quantity of pork; providing housing facilities, temperature and humidity control, food...
Poland: acetic acid market
By - Williams and Marshal Strategy
until 2018. In the same way, the report presents an elaborate overview of the main market participants, the price fluctuations, the growth and demand drivers of the market and the factors, influencing its development. Last but not least, the report presents a general overview of the economy of Poland in 2008-2012 and a forecast for its development in the medium term. The report on the acetic acid market in Poland includes: Analysis and dynamics of the economy of Poland; Forecast for the development of the economy of Poland; Analysis and forecast of market volume and dynamics; Volume,...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Warren Buffet Helps Burger King with Tim Horton Deal
Aug 27, 2014  
Renowned investor Warren Buffet plans to finance Burger King Worldwide Inc.’s acquisition of Tim Hortons Inc., the Canadian coffee chain. Berkshire Hathaway Inc., Warren Buffet’s firm will invest through preferred shares, it is speculated. Nearly 25% of the deal’s financing would be handled by Berkshire. The precise aim for Warren Buffet’s participation is yet...
Anti-UAW Workers to Form Another Union at Volkswagen Plant
Aug 27, 2014  
Employees at the Chattanooga plant of Volkswagen AG are trying to form a union of company’s salaried and hourly workers, as a means to counter the United Auto Workers Local 42 union that was established last month.  The new union is expected to force Volkswagen in rethinking and holding another vote to determine which union is favored by hourly employees. UAV had earlier...
Fairchild Axing 15% of its Workforce with Multiple Plant Closures
Aug 27, 2014  
American semiconductor manufacturer Fairchild has said that it will be laying off nearly 15% of its global workforce following the closure of its facilities in Malaysia, Utah, and Korea. The company will cease the production of five-inch silicon from its plant in Bucheon, Korea. It will also scale down its capacity to produce six-inch wafers. The company will bring these closures into effect...